Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson To Commercialize New Emergency Contraceptive In US
UPA is a new emergency contraceptive developed by HRA Pharma specifically for emergency contraceptive use, that is approved and marketed by HRA Pharma in Europe as ellaOne since
UPA is a new emergency contraceptive developed by HRA Pharma specifically for emergency contraceptive use, that is approved and marketed by HRA Pharma in Europe as ellaOne since
Actavis became the owner of Norgesplaster in December 2005, following the acquisition of the generics division of Alpharma. Actavis’ focus remains on its core business, generic pharmaceuticals. Actavis
The company said that its new facility provides 50% and 100% greater manufacturing capacity, respectively, than its existing facility. Robin Smith, chairman and CEO of NeoStem, said: “This
As per the agreement, Cordis will receive $1.725 billion from Boston Scientific and Johnson & Johnson expects to record the majority of this payment as a special item
Luliconazole is a potent and broad-spectrum topical antifungal agent in development and will be advancing to phase 3 clinical development in the US for tinea pedis (athlete’s foot).
The clinical trial is being conducted in approximately 25 sites across the US and is expected to enroll 440 adult patients with acute uncomplicated influenza. It is also
Paul Simboli, senior director of Intellectual Property at Depomed, has noted that with the issuance of the additional patent, the company expects to hold six US patents covering
The company said that the protocol provides a simple, three-step testing algorithm that can be customized based upon a patient’s symptoms and history. Step one provides a screen
The Establishment License issued by Health Canada will enable Dalton to continue to manufacture, test and ship sterile commercial products for its existing clients. In addition, Dalton’s solid
The exclusive license grants GCAT the right, through its Chinese joint venture with Tianjing Institute of Pharmaceutical Research, to clinically develop and commercialize elvucitabine in mainland China, Hong